![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/04/2893106/15114/en/Lumos-Pharma-Announces-New-Analyses-of-Phase-2-OraGrowtH212-Trial-Presented-at-ENDO-2024.html
https://www.globenewswire.com/news-release/2024/05/20/2885136/15114/en/Lumos-Pharma-Announces-Abstracts-Accepted-for-Presentation-at-ENDO-2024.html
https://www.globenewswire.com/news-release/2024/05/14/2881908/15114/en/Lumos-Pharma-Announces-Positive-End-of-Phase-2-Meeting-with-FDA-and-Reports-First-Quarter-2024-Financial-Results.html
https://www.globenewswire.com/news-release/2024/05/09/2879084/15114/en/Lumos-Pharma-to-Report-First-Quarter-2024-Financial-Results-and-Provide-Clinical-Update-on-May-15-2024.html
https://www.globenewswire.com/news-release/2024/04/18/2865819/15114/en/Lumos-Pharma-Announces-Abstracts-Accepted-for-Presentation-at-Upcoming-Medical-Meetings.html
https://www.globenewswire.com/news-release/2024/03/20/2849307/15114/en/Lumos-Pharma-Announces-that-the-USPTO-Has-Granted-Patent-Protection-for-Novel-Formulation-of-LUM-201-Extending-Exclusivity-to-2042.html
https://www.globenewswire.com//news-release/2024/03/07/2842720/15114/en/Lumos-Pharma-Reports-Full-Year-2023-Financial-Results-and-Provides-Clinical-Development-Update.html
https://www.globenewswire.com//news-release/2024/02/26/2835146/15114/en/Lumos-Pharma-to-Report-Full-Year-2023-Financial-Results-and-Host-Conference-Call-on-March-7-2024.html
https://www.globenewswire.com//news-release/2024/02/05/2823843/15114/en/Lumos-Pharma-to-Participate-in-Oppenheimer-s-34th-Annual-Healthcare-Life-Sciences-Conference.html
https://www.globenewswire.com//news-release/2024/01/04/2804321/15114/en/Lumos-Pharma-Promotes-Pisit-Duke-Pitukcheewanont-MD-to-Chief-Medical-Officer.html